

## Contents

### Response Assessment in Solid Tumours (RECIST):

#### Version 1.1 and supporting papers

Guest Editors: E. Eisenhauer, J. Verweij and P. Therasse

Cancer clinical trial outcomes: Any progress in tumour-size assessment? <i>J. Verweij, P. Therasse and E. Eisenhauer, on behalf of the RECIST working group</i>	225
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) <i>E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe and J. Verweij</i>	228
Individual patient data analysis to assess modifications to the RECIST criteria <i>J. Bogaerts, R. Ford, D. Sargent, L.H. Schwartz, L. Rubinstein, D. Lacombe, E. Eisenhauer, J. Verweij and P. Therasse, for the RECIST Working Party</i>	248
Evaluation of lymph nodes with RECIST 1.1 <i>L.H. Schwartz, J. Bogaerts, R. Ford, L. Shankar, P. Therasse, S. Gwyther and E.A. Eisenhauer</i>	261
Lessons learned from independent central review <i>R. Ford, L. Schwartz, J. Dancey, L.E. Dodd, E.A. Eisenhauer, S. Gwyther, L. Rubinstein, D. Sargent, L. Shankar, P. Therasse and J. Verweij</i>	268
Optimising the design of phase II oncology trials: The importance of randomisation <i>M.J. Ratain and D.J. Sargent</i>	275
Recommendations for the assessment of progression in randomised cancer treatment trials <i>J.E. Dancey, L.E. Dodd, R. Ford, R. Kaplan, M. Mooney, L. Rubinstein, L.H. Schwartz, L. Shankar and P. Therasse</i>	281
Validation of novel imaging methodologies for use as cancer clinical trial end-points <i>D.J. Sargent, L. Rubinstein, L. Schwartz, J.E. Dancey, C. Gatsonis, L.E. Dodd and L.K. Shankar</i>	290
A simulation study to evaluate the impact of the number of lesions measured on response assessment <i>C.S. Moskowitz, X. Jia, L.H. Schwartz and M. Gönen</i>	300

